Pluripotent iPS cells from the iPS Core
Facility at Karolinska Institutet
Disease-specific iPS cell lines open up unique opportunities to study the mechanisms of human disease and ultimately to develop new treatments.
The iPS Core facility at Karolinska Institutet in Stockholm, Sweden, provides a reprogramming service to supply scientists with human induced pluripotent stem (iPS) cells. Services include fibroblast derivation, reprogramming, characterization, banking, and training. The human iPS clones are derived from human fibroblasts using the Yamanaka factors integrated by Sendai viruses, a non-integrating method free from any footprint. The human iPSC cells are cultivated and passaged on laminin-521 (LN521™) in E8 medium. All clones undergo basic quality controls (mycoplasma test, gene expression of viral vectors, pluripotent gene expression) before delivery. Additional tests can be arranged upon request.
Visit the iPS Core Facility's web-page for culture protocols and more information regarding core services and prices.
"We at the iPS core at Karolinska Institutet use laminin-521 for derivation and maintenance of our iPS cells. It is reliable, consistent and user-friendly for us and for our customers."
Malin Kele, Sr Lab Manager, iPS Core/Anna Falk lab, Karolinska Institutet, Sweden